Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Rhabdomyosarcoma: early-phase trial registry
17 of 36 indexed Rhabdomyosarcoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #419 of 28,707 conditions by registered trial count.
36 US clinical trials · 17 currently recruiting · #419 of 28,707 conditions by registered trial count
Rhabdomyosarcoma: 36 US clinical trials tracked, 17 recruiting.
Rhabdomyosarcoma is the subject of 36 registered US clinical trials on ClinicalTrials.gov, 17 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 33 in Phase 1-2 (earlier-stage). The most active sponsor is Baylor College of Medicine, running 6 of these trials.
Enrollment posture brief
Registry condition rhabdomyosarcoma
OPEN 17 | RECR 47% | LATE 2 | EARLY 33 | RANK #419 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Crohn Disease (47% recruiting · 72 trials)
Rhabdomyosarcoma lists 17 open slots (47% of 36 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Rhabdomyosarcoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Rhabdomyosarcoma is recruiting above its size-band peers.
17 of 36 indexed trials (47.2%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Rhabdomyosarcoma research.
Baylor College of Medicine accounts for 6 of 36 trials (16.7%). 22 distinct sponsors appear on at least one study for this condition label.
-
Most Rhabdomyosarcoma trials plan to enrol fewer than 100 people.
Median target enrolment is 30 among the 36 trials that report a genuine target (sentinel values excluded). 29 of those (80.6%) plan for fewer than 100 participants.
-
Rhabdomyosarcoma research is mostly interventional.
36 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
36 total, page 1 of 1
Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
St. Jude Children's Research Hospital
NCT06023641
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Milton S. Hershey Medical Center
NCT06541262
Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06796543
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
David S Shulman, MD
NCT06709495
FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma
National Cancer Institute (NCI)
NCT06865664
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
Iovance Biotherapeutics
NCT06566092
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
St. Jude Children's Research Hospital
NCT04897321
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
University of Florida
NCT06625190
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
Baylor College of Medicine
NCT04995003
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Baylor College of Medicine
NCT04715191
VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
University of Texas Southwestern Medical Center
NCT04796012
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
University of Wisconsin, Madison
NCT02508038
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
Baylor College of Medicine
NCT06198296
Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
Seattle Children's Hospital
NCT07148050
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
ITM Solucin
NCT06441331
Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
Valent Technologies
NCT04337177
Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
Children's National Research Institute
NCT07172958
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
National Cancer Institute (NCI)
NCT02567435
Radiation Therapy to Treat Musculoskeletal Tumors
St. Jude Children's Research Hospital
NCT00186992
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
Pfizer
NCT03709680
Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy
St. Jude Children's Research Hospital
NCT01871766
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Seattle Children's Hospital
NCT04483778
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Seattle Children's Hospital
NCT03618381
Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma
Jonsson Comprehensive Cancer Center
NCT04299113
Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas
Cellectar Biosciences
NCT03478462
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Baylor College of Medicine
NCT04377932
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors
Baylor College of Medicine
NCT05103631
Evolutionary Therapy for Rhabdomyosarcoma
H. Lee Moffitt Cancer Center and Research Institute
NCT04388839
Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma
Children's Oncology Group
NCT00354835
New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma
National Cancer Institute (NCI)
NCT00001335
Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy
St. Jude Children's Research Hospital
NCT00187109
A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas
National Cancer Institute (NCI)
NCT00001564
A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping
Cardinal Health 414
NCT02509598
Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma
University of Louisville
NCT01241162
HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors
Timothy Cripe
NCT00931931
TAA-Specific CTLS for Solid Tumors (TACTASOM)
Baylor College of Medicine
NCT02239861
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 25 |
| Phase 2 | 8 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Rhabdomyosarcoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Rhabdomyosarcoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Rhabdomyosarcoma page
36 registered trials, 17 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 17 Rhabdomyosarcoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Baylor College of Medicine sponsors the most Rhabdomyosarcoma trials on record, review their full trial history before evaluating a specific study. See Baylor College of Medicine's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Rhabdomyosarcoma condition card totals 36 registered trials; most-linked intervention Cyclophosphamide; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.